{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:38:12Z","timestamp":1790127492819,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BDJ Open"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Drug-associated gingival disorders can negatively impact on oral health. This study aimed to utilize the United States Food and Drug Administration Adverse Event Reporting System (USFDA AERS) to comprehensively assess the associations between medications and specific gingival disorders.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Data were extracted from the USFDA AERS from 2004-2024 using Preferred Terms for eight gingival disorders. Reports were deduplicated and disproportionality analysis was conducted using frequentist and Bayesian approaches to detect potential signals. Volcano plots were generated for each gum disorder to identify the drugs with the strongest signals based on the statistical significance and magnitude of association.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 11,465 reports were included. Several anti-osteoporotic drugs, anti-thrombotics, calcium channel blockers and immunosuppressants showed significant associations with multiple gingival disorders. Phenytoin was linked to hypertrophy and bleeding. Stomatological preparations were associated with discoloration and bleeding. Emergent signals were identified with finasteride, COVID-19 vaccine, and levothyroxine with gum disorders.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study highlights the need for increased awareness of oral side effects amongst healthcare providers. Future research should explore the mechanisms of drug-induced gingival disorders and develop interdisciplinary management strategies to enhance oral health in patients on long-term medications.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41405-024-00291-8","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T12:54:10Z","timestamp":1741697650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Drug-associated gingival disorders: a retrospective pharmacovigilance assessment using disproportionality analysis"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3811-6503","authenticated-orcid":false,"given":"Kannan","family":"Sridharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5877-205X","authenticated-orcid":false,"given":"Gowri","family":"Sivaramakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"291_CR1","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1177\/0022034515571265","volume":"94","author":"PC Trackman","year":"2015","unstructured":"Trackman PC, Kantarci A. Molecular and clinical aspects of drug-induced gingival overgrowth. J Dent Res. 2015;94:540\u20136.","journal-title":"J Dent Res"},{"key":"291_CR2","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.3390\/app12083731","volume":"12","author":"D De Falco","year":"2022","unstructured":"De Falco D, Della Vella F, Scivetti M, Suriano C, De Benedittis M, Petruzzi M. Non-Plaque Induced Diffuse Gingival Overgrowth: An Overview. Appl Sci. 2022;12:3731.","journal-title":"Appl Sci"},{"key":"291_CR3","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1902\/jop.2001.72.7.921","volume":"72","author":"MI Uzel","year":"2001","unstructured":"Uzel MI, Kantarci A, Hong HH, Uygur C, Sheff MC, Firatli E, et al. Connective tissue growth factor in drug-induced gingival overgrowth. J Periodontol. 2001;72:921\u201331.","journal-title":"J Periodontol"},{"key":"291_CR4","unstructured":"Tungare S, Paranjpe AG. Drug-Induced Gingival Overgrowth. [Updated 2022 Sep 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538518\/."},{"key":"291_CR5","doi-asserted-by":"publisher","unstructured":"Anil SHSA, Alyafei S, Kitty George A, Paul Chalisserry E. Adverse Effects of Medications on Periodontal Tissues. Oral Diseases. IntechOpen; 2020. Available from: https:\/\/doi.org\/10.5772\/intechopen.92166 (Accessed on 27th October 2024).","DOI":"10.5772\/intechopen.92166"},{"key":"291_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2478\/jim-2023-0001","volume":"8","author":"E Kis","year":"2023","unstructured":"Kis E, Lazar A, Lazar L. Drug-Induced Changes in the Gingival Tissue. J Interdiscip Med. 2023;8:1\u20135.","journal-title":"J Interdiscip Med"},{"key":"291_CR7","first-page":"613","volume":"102","author":"A Glick","year":"2020","unstructured":"Glick A, Sista V, Johnson C. Oral Manifestations of Commonly Prescribed Drugs. Am Fam Physician. 2020;102:613\u201321.","journal-title":"Am Fam Physician"},{"key":"291_CR8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.12998\/wjcc.v3.i9.779","volume":"3","author":"AA Agrawal","year":"2015","unstructured":"Agrawal AA. Gingival enlargements: Differential diagnosis and review of literature. World J Clin Cases. 2015;3:779\u201388.","journal-title":"World J Clin Cases"},{"key":"291_CR9","unstructured":"Potential Signals of Serious Risks\/New Safety Information Identified from the FDA Adverse Event Reporting System (FAERS). Available at: https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/potential-signals-serious-risksnew-safety-information-identified-fda-adverse-event-reporting-system (Accessed on November 3, 2024)."},{"key":"291_CR10","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s40272-024-00657-3","volume":"26","author":"K Sridharan","year":"2024","unstructured":"Sridharan K, Sivaramakrishnan G. Adverse Event Profile of First-line Drugs for Treating Patent Ductus Arteriosus in Neonates: A Disproportionality Analysis Study of USFDA Adverse Event Reporting System. Paediatr Drugs. 2024;26:767\u201385.","journal-title":"Paediatr Drugs"},{"key":"291_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-017-0088-5","volume":"3","author":"H Hatahira","year":"2017","unstructured":"Hatahira H, Abe J, Hane Y, Matsui T, Sasaoka S, Motooka Y, et al. Drug-induced gingival hyperplasia: a retrospective study using spontaneous reporting system databases. J Pharm Health Care Sci. 2017;3:19.","journal-title":"J Pharm Health Care Sci"},{"key":"291_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1600-051X.2012.01878.x","volume":"39","author":"E Bondon-Guitton","year":"2012","unstructured":"Bondon-Guitton E, Bagheri H, Montastruc JL. Drug-induced gingival overgrowth: a study in the French Pharmacovigilance Database. J Clin Periodontol. 2012;39:513\u20138.","journal-title":"J Clin Periodontol"},{"key":"291_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20:109\u201317.","journal-title":"Drug Saf"},{"key":"291_CR14","unstructured":"FDA Adverse Event Reporting System (FAERS) Public Dashboard. Available at: https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard (Accessed on November 3, 2024)."},{"key":"291_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"JL Faillie","year":"2019","unstructured":"Faillie JL. Case-non-case studies: Principle, methods, bias and interpretation. Therapie. 2019;74:225\u201332.","journal-title":"Therapie"},{"key":"291_CR16","unstructured":"Practical aspects of signal detection in pharmacovigilance. Report of CIOMS working group VIII. Geneva, Switzerland: World Health Organization; 2010."},{"key":"291_CR17","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1002\/1097-0258(20001215)19:23<3199::AID-SIM621>3.0.CO;2-Q","volume":"19","author":"SJ Evans","year":"2000","unstructured":"Evans SJ. Pharmacovigilance: a science or fielding emergencies? Stat Med. 2000;19:3199\u2013209.","journal-title":"Stat Med"},{"key":"291_CR18","unstructured":"WHO Anatomical Therapeutic Chemical (ATC) Classification. Available at: https:\/\/www.whocc.no\/atc\/structure_and_principles\/ (Accessed on November 3, 2024)."},{"key":"291_CR19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, et al. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration. Drug Saf. 2024;47:585\u201399.","journal-title":"Drug Saf"},{"key":"291_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-76603-3","volume":"10","author":"J Goedhart","year":"2020","unstructured":"Goedhart J, Luijsterburg MS. VolcaNoseR is a web app for creating, exploring, labeling and sharing volcano plots. Sci Rep. 2020;10:20560.","journal-title":"Sci Rep"},{"key":"291_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1367607","volume":"15","author":"L Wang","year":"2024","unstructured":"Wang L, Zhang W, Zhao CL, Fu ZH. Bisphosphonate- and disumab-related gingival disorders: case analysis from the U.S. Food and Drug Administration Adverse Event Reporting System. Front Endocrinol. 2024;15:1367607.","journal-title":"Front Endocrinol"},{"key":"291_CR22","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.joms.2013.08.007","volume":"72","author":"NM McLeod","year":"2014","unstructured":"McLeod NM, Moutasim KA, Brennan PA, Thomas G, Jenei V. In vitro effect of bisphosphonates on oral keratinocytes and fibroblasts. J Oral Maxillofac Surg. 2014;72:503\u20139.","journal-title":"J Oral Maxillofac Surg"},{"key":"291_CR23","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/JPER.19-0385","volume":"91","author":"N Taniguchi","year":"2020","unstructured":"Taniguchi N, Osaki M, Onuma K, Ishikawa M, Ryoke K, Kodani I, et al. Bisphosphonate-induced reactive oxygen species inhibit proliferation and migration of oral fibroblasts: A pathogenesis of bisphosphonate-related osteonecrosis of the jaw. J Periodontol. 2020;91:947\u201355.","journal-title":"J Periodontol"},{"key":"291_CR24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.2174\/1874210600903010114","volume":"3","author":"E Markou","year":"2009","unstructured":"Markou E, Eleana B, Lazaros T, Antonios K. The influence of sex steroid hormones on gingiva of women. Open Dent J. 2009;3:114\u20139.","journal-title":"Open Dent J"},{"key":"291_CR25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/00003086-200102000-00031","volume":"383","author":"D Yu","year":"2001","unstructured":"Yu D, Panossian V, Hatch D, Liu H, Finerman A. Combined effects of estrogen and progesterone on the anterior cruciate ligament. Clin Orthop. 2001;383:268\u201381.","journal-title":"Clin Orthop"},{"key":"291_CR26","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1177\/036354659702500521","volume":"25","author":"H Liu","year":"1997","unstructured":"Liu H, Al-Shaikh A, Panossian V, Finerman A, Lane M. Estrogen affects the cellular metabolism of the anterior cruciate ligament. A potential explanation for female athletic injury. Am J Sports Med. 1997;25:704\u20139.","journal-title":"Am J Sports Med"},{"key":"291_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2147\/CCIDE.S431814","volume":"15","author":"SA AlGhamdi","year":"2023","unstructured":"AlGhamdi SA, Altowairqi K, Altowairqi YG, Alkharobi H, Alfayez E, Mansouri R, et al. Health Effects of Oral Contraceptives on Periodontal Disease and Gingivitis: A Cross-Sectional Questionnaire-Based Study Among Saudi Women in Jeddah. Clin Cosmet Investig Dent. 2023;15:237\u201344.","journal-title":"Clin Cosmet Investig Dent"},{"key":"291_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12905-021-01180-0","volume":"21","author":"MML Castro","year":"2021","unstructured":"Castro MML, Ferreira MKM, Prazeres IEE, de Oliveira Nunes PB, Magno MB, R\u00f6sing CK, et al. Is the use of contraceptives associated with periodontal diseases? A systematic review and meta-analyses. BMC Womens Health. 2021;21:48.","journal-title":"BMC Womens Health"},{"key":"291_CR29","unstructured":"Summary package insert of Ortho Tri-Cyclen. Available at: chrome-extension: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/021690ppi.pdf (Accessed on November 3, 2024)."},{"key":"291_CR30","unstructured":"Denosumab package insert. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125320s5s6lbl.pdf (Accessed on November 3, 2024)."},{"key":"291_CR31","unstructured":"Alendronate package insert. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021575s017lbl.pdf (Accessed on November 3, 2024)."},{"key":"291_CR32","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1600-0765.1996.tb00498.x","volume":"31","author":"SC Kasasa","year":"1996","unstructured":"Kasasa SC, Soory M. The synthesis of 5-alphadihydrotestosterone from androgens by human gingival tissues and fibroblasts in culture in response to TGF-beta and PDGF. J Periodontal Res. 1996;31:313\u201322.","journal-title":"J Periodontal Res"},{"key":"291_CR33","doi-asserted-by":"publisher","first-page":"506","DOI":"10.4103\/0976-237X.194099","volume":"7","author":"R Hosadurga","year":"2016","unstructured":"Hosadurga R, Nabeel Althaf MS, Hegde S, Rajesh KS, Arun Kumar MS. Influence of sex hormone levels on gingival enlargement in adolescent patients undergoing fixed orthodontic therapy: A pilot study. Contemp Clin Dent. 2016;7:506\u201311.","journal-title":"Contemp Clin Dent"},{"key":"291_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1600-051X.1998.tb02365.x","volume":"25","author":"M Soory","year":"1998","unstructured":"Soory M, Virdi H. Effects of the anti-androgen finasteride on 5alpha-reductase activity in human gingival fibroblasts in response to minocycline. J Clin Periodontol. 1998;25:67\u201373.","journal-title":"J Clin Periodontol"},{"key":"291_CR35","doi-asserted-by":"publisher","first-page":"752","DOI":"10.3390\/biology10080752","volume":"10","author":"M Klugar","year":"2021","unstructured":"Klugar M, Riad A, Mekhemar M, Conrad J, Buchbender M, Howaldt HP, et al. Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers. Biology. 2021;10:752.","journal-title":"Biology"},{"key":"291_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12903-022-02100-w","volume":"22","author":"Y Chun","year":"2022","unstructured":"Chun Y, Jang J, Jo JH, Park JW. Various painful oral adverse reactions following COVID-19 vaccination: a case series. BMC Oral Health. 2022;22:64.","journal-title":"BMC Oral Health"},{"key":"291_CR37","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/jcpe.13435","volume":"48","author":"N Marouf","year":"2021","unstructured":"Marouf N, Cai W, Said KN, Daas H, Diab H, Chinta VR, et al. Association between periodontitis and severity of COVID-19 infection: A case-control study. J Clin Periodontol. 2021;48:483\u201391.","journal-title":"J Clin Periodontol"},{"key":"291_CR38","doi-asserted-by":"publisher","DOI":"10.5402\/2013\/215690","volume":"2013","author":"S Viswanathan","year":"2013","unstructured":"Viswanathan S. Urine bag as a modern day matula. ISRN Nephrol. 2013;2013:215690.","journal-title":"ISRN Nephrol"},{"key":"291_CR39","doi-asserted-by":"publisher","first-page":"535","DOI":"10.4103\/jisp.jisp_316_18","volume":"22","author":"SI Rahangdale","year":"2018","unstructured":"Rahangdale SI, Galgali SR. Periodontal status of hypothyroid patients on thyroxine replacement therapy: A comparative cross-sectional study. J Indian Soc Periodontol. 2018;22:535\u201340.","journal-title":"J Indian Soc Periodontol"},{"key":"291_CR40","doi-asserted-by":"publisher","unstructured":"Raschi E, Moretti U, Salvo F, Pariente A, Cosimo Antonazzo I, De Ponti F, et al. Evolving Roles of Spontaneous Reporting Systems to Assess and Monitor Drug Safety [Internet]. Pharmacovigilance. IntechOpen; 2019. Available from: https:\/\/doi.org\/10.5772\/intechopen.79986 (Accessed on December 4, 2024).","DOI":"10.5772\/intechopen.79986"},{"key":"291_CR41","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40264-023-01345-w","volume":"46","author":"V Giunchi","year":"2023","unstructured":"Giunchi V, Fusaroli M, Hauben M, Raschi E, Poluzzi E. Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach. Drug Saf. 2023;46:921\u20136.","journal-title":"Drug Saf"},{"key":"291_CR42","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40264-017-0523-4","volume":"40","author":"K Kreimeyer","year":"2017","unstructured":"Kreimeyer K, Menschik D, Winiecki S, Paul W, Barash F, Woo EJ, et al. Using Probabilistic Record Linkage of Structured and Unstructured Data to Identify Duplicate Cases in Spontaneous Adverse Event Reporting Systems. Drug Saf. 2017;40:571\u201382.","journal-title":"Drug Saf"}],"container-title":["BDJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41405-024-00291-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41405-024-00291-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41405-024-00291-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T12:54:13Z","timestamp":1741697653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41405-024-00291-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["291"],"URL":"https:\/\/doi.org\/10.1038\/s41405-024-00291-8","relation":{},"ISSN":["2056-807X"],"issn-type":[{"value":"2056-807X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"9 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}